Early identification of cardiovascular risk using genomics and proteomics.
Early identification of cardiovascular risk using genomics and proteomics.
复制标题
DOI：
10.1038/nrcardio.2010.53
复制
发表时间：
2010-06
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
冠心病（CHD）将很快成为世界上主要的死亡和发病原因。因此，冠心病的早期发现和治疗对于改善全球健康至关重要。冠状动脉粥样硬化是一个复杂的多因素疾病过程，涉及多个途径，可受遗传和环境因素的影响。随着基因组学和蛋白质组学的最新进展，可能会发现许多具有小到中度影响的新风险因素。此外，个性化的风险分层和靶向治疗可能变得可行;每个人都可能通过一组基因组和蛋白质组标记物的测试进行评估，并根据个人的综合风险状况，然后采取预防和治疗步骤。通过多标记物方法，也有可能识别动脉粥样硬化形成相关通路的改变，而不是关注单个风险因素。本文以动脉粥样硬化为例，探讨基因组学和蛋白质组学在心血管风险评估中的作用。
Coronary heart disease (CHD) will soon become the leading cause of death and morbidity in the world. Early detection and treatment of CHD is thus imperative to improve global health. Atherosclerosis of the coronary arteries is a complex multifactorial disease process involving multiple pathways that can be influenced by both genetic and environmental factors. With the recent advances in genomics and proteomics, many new risk factors with small-to-moderate effects are likely to be identified. Additionally, individualized risk stratification and targeted therapy may become feasible; each individual could potentially be assessed with a panel of tests for genomic and proteomic markers and, on the basis of the individual’s composite risk profile, preventive and therapeutic steps could then be undertaken. With a multimarker approach, it may also be possible to identify alterations in pathways involved in atherogenesis, rather than focus on individual risk factors. In this article, we use the specific example of atherosclerosis to discuss the role of genomics and proteomics in cardiovascular risk assessment.